About C R Bard (NYSE:BCR)

C. R. Bard, Inc. (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis. Its vascular products cover a range of minimally invasive devices for the treatment of peripheral vascular disease and end-stage renal disease. Its urology products include basic urology drainage products, fecal and urinary continence products, urological specialty products and Targeted Temperature Management products. Its oncology products cover a range of devices used in the treatment and management of various cancers, and other diseases and disorders. Its surgical specialty products include implanted patches and fixation devices for hernia and soft tissue repairs.

Receive BCR News and Ratings via Email

Sign-up to receive the latest news and ratings for BCR and its competitors with MarketBeat's FREE daily newsletter.

Profitability

Miscellaneous

C R Bard (NYSE:BCR) Frequently Asked Questions

What is C R Bard's stock symbol?

C R Bard trades on the New York Stock Exchange (NYSE) under the ticker symbol "BCR."

How often does C R Bard pay dividends? What is the dividend yield for C R Bard?

C R Bard declared a quarterly dividend on Wednesday, October 11th. Investors of record on Friday, December 8th will be given a dividend of $0.26 per share on Friday, December 29th. This represents a $1.04 annualized dividend and a yield of Infinity. The ex-dividend date is Thursday, December 7th. View C R Bard's Dividend History.

How were C R Bard's earnings last quarter?

C R Bard Inc (NYSE:BCR) released its quarterly earnings results on Wednesday, October, 25th. The medical instruments supplier reported $3.02 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $2.96 by $0.06. The medical instruments supplier had revenue of $989.80 million for the quarter, compared to analyst estimates of $990.64 million. C R Bard had a return on equity of 19.39% and a net margin of 9.51%. C R Bard's revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter last year, the company posted $2.64 earnings per share. View C R Bard's Earnings History.

Where is C R Bard's stock going? Where will C R Bard's stock price be in 2018?

What are Wall Street analysts saying about C R Bard stock?

Here are some recent quotes from research analysts about C R Bard stock:

1. According to Zacks Investment Research, "In the last year, C. R. Bard has outperformed the broader industry trends with respect to price performance. Looking forward C. R. Bard is expected to benefit from the impending merger with Becton, Dickinson and Company, especially in the areas of medication management and infection prevention. The $24 billion transaction is expected to close in the fourth quarter of 2017. We believe the development will provide benefits to the combined entity and bolster its foothold in the global medical devices market. The growing adoption of Lutonix DCB is also expected to drive top-line growth in the coming quarters.However, a challenging Med-tech environment is a major concern. The company witnesses significant pricing pressure as well. Additionally, cutthroat competition in the hernia fixation and peripheral stent businesses are likely to dent growth. " (12/26/2017)

2. Needham & Company LLC analysts commented, "BCR’s 3Q17 revenue missed and EPS beat consensus and management raised its 2017 revenue and EPS guidance. Revenue growth slowed somewhat to 5.0% in 3Q17 from 6.4% in 2Q17 as three of four segments missed consensus. Revenue growth faced a 1.5% headwind, attributable to the impact from the hurricanes and a Surgical Sealant supply issue, both equally. We have maintained our revenue and EPS estimates." (10/26/2017)

Has C R Bard been receiving favorable news coverage?

News articles about BCR stock have been trending somewhat positive on Monday, Accern Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. C R Bard earned a news sentiment score of 0.12 on Accern's scale. They also gave headlines about the medical instruments supplier an impact score of 49.22 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of C R Bard?

Shares of BCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How big of a company is C R Bard?

C R Bard has a market capitalization of $24.14 billion and generates $3.71 billion in revenue each year. The medical instruments supplier earns $531.40 million in net income (profit) each year or $7.59 on an earnings per share basis. C R Bard employs 16,300 workers across the globe.

MarketBeat Community Rating for C R Bard (BCR)

MarketBeat's community ratings are surveys of what our community members think about C R Bard and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

C R Bard (NYSE:BCR) Analysts' Consensus Rating

MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.

MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.